Literature DB >> 10698513

Inhibition of H-Ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene.

T Tolkacheva1, A M Chan.   

Abstract

The human PTEN/MMAC1/TEP1 (PTEN) tumor suppressor gene encodes a phosphatase with specificity towards the D3 phosphate of phosphatidylinositides. PTEN mutations have been reported in the endometrioid type of uterine tumors which are associated with frequent activations of the Ras oncogenes. In this study, we report the ability of PTEN to potently inhibit H-Ras induced morphological transformation and anchorage-independent growth in NIH3T3 cells. This novel activity of PTEN was correlated more with its ability to suppress the phosphatidylinositol 3-kinase (PI3-K)-dependent signaling cascade, but not the mitogen-activated protein kinase (MAPK) pathway. To define the minimal region in PTEN protein that is responsible for this anti-oncogenic activity, a panel of carboxyl-terminal truncation mutants was generated. While deletions of 4 and 33 amino acids do not have marked effects, removal of up to 68 amino acids drastically reduced the ability of PTEN to inhibit Ras transformation. The propensity of these mutants to suppress Ras transformation is correlated with their relative ability to dephosphorylate inositol (1,3,4,5)-tetrakisphosphate in vitro, and to suppress Akt kinase activity in cultured cells. In addition, we have evidence to suggest that the C-terminal region of PTEN contributes to the stability of the encoded gene product.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698513     DOI: 10.1038/sj.onc.1203331

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  Membrane-binding and activation mechanism of PTEN.

Authors:  Sudipto Das; Jack E Dixon; Wonhwa Cho
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

2.  Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma.

Authors:  Martina Rudelius; Stefania Pittaluga; Satoshi Nishizuka; Trinh H-T Pham; Falko Fend; Elaine S Jaffe; Leticia Quintanilla-Martinez; Mark Raffeld
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

3.  TPIP: a novel phosphoinositide 3-phosphatase.

Authors:  S M Walker; C P Downes; N R Leslie
Journal:  Biochem J       Date:  2001-12-01       Impact factor: 3.857

4.  The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization.

Authors:  Fatemeh Fouladkou; Tamara Landry; Hiroshi Kawabe; Antje Neeb; Chen Lu; Nils Brose; Vuk Stambolic; Daniela Rotin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-18       Impact factor: 11.205

5.  Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer.

Authors:  Kentaro Iwanaga; Yanan Yang; Maria Gabriela Raso; Lijiang Ma; Amy E Hanna; Nishan Thilaganathan; Seyed Moghaddam; Christopher M Evans; Huaiguang Li; Wei-Wen Cai; Mitsuo Sato; John D Minna; Hong Wu; Chad J Creighton; Francesco J Demayo; Ignacio I Wistuba; Jonathan M Kurie
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

Review 6.  PTEN function: how normal cells control it and tumour cells lose it.

Authors:  Nick R Leslie; C Peter Downes
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

Review 7.  PTEN and the PI3-kinase pathway in cancer.

Authors:  Nader Chalhoub; Suzanne J Baker
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

Review 8.  Peroxiredoxin 1 and its role in cell signaling.

Authors:  Carola A Neumann; Juxiang Cao; Yefim Manevich
Journal:  Cell Cycle       Date:  2009-12-05       Impact factor: 4.534

9.  Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity.

Authors:  Juxiang Cao; Jennifer Schulte; Alexander Knight; Nicholas R Leslie; Agnieszka Zagozdzon; Roderick Bronson; Yefim Manevich; Craig Beeson; Carola A Neumann
Journal:  EMBO J       Date:  2009-04-16       Impact factor: 11.598

10.  Statistical method on nonrandom clustering with application to somatic mutations in cancer.

Authors:  Jingjing Ye; Adam Pavlicek; Elizabeth A Lunney; Paul A Rejto; Chi-Hse Teng
Journal:  BMC Bioinformatics       Date:  2010-01-07       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.